Opendata, web and dolomites

AmInnovation SIGNED

Disruptive Innovation to Treat Alzheimer’s and Parkinson’s diseases: new target, new patented drug, new therapeutic strategy.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AmInnovation project word cloud

Explore the words cloud of the AmInnovation project. It provides you a very rough idea of what is the project "AmInnovation" about.

publications    culprits    first    anti    wrong    oligomers    medical    alzheimer    membrane    owned    overdose    molecular    people    biological    million    totally    pores    stop    strategies    century    double    trials    21st    scientific    code    neurotoxic    additional    intelligence    social    counts    disease    clinical    position    fact    demonstrated    correlation    unsuccessful    artificial    neurological    revolutions    2018    firstly    quite    exclusive    innovation    paradigm    candidate    drug    overcome    relying    patent    license    block    disruptive    conclusive    tests    2050    cells    secondly    diseases    progression    neurosciences    action    responsible    global    linking    financial    solution    terrible    neurodegenerative    amyloid    protein    amypore    brain    amyp53    rely    pathologies    world    inventors    direct    advantages    linked    disorders    paradigms    plaques    cure    administer    plan    calcium    international    immunotherapies    mechanisms    symptoms    optimizing    oligomer    academic    incriminate    cascade    parkinson    worldwide   

Project "AmInnovation" data sheet

The following table provides information about the project.

Coordinator
AMYPORE 

Organization address
address: BOULEVARD ELIE CORRADI 51
city: SEPTEMES-LES-VALLONS
postcode: 13240
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.amypore.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AMYPORE FR (SEPTEMES-LES-VALLONS) coordinator 50˙000.00

Map

 Project objective

Neurodegenerative disorders represent the most important medical, social and financial challenges for the 21st century. In 2018, the world counts 50 million people with Alzheimer’s disease and 7 million with Parkinson’s disease, and the number of cases will double before 2050. The current medical paradigms, which incriminate amyloid plaques as the main culprits of these pathologies, do not provide a cure or even stop the progression of the diseases. All clinical trials based on anti-plaques immunotherapies have been unsuccessful. The reason for this global failure is quite simple: these strategies are based on the wrong targets. Indeed, there is no correlation at all between the neurological symptoms and the presence of amyloid plaques in the brain. Thus, the paradigm linking amyloid plaques to neurodegenerative diseases has been totally wrong.

AmyPore action plan has been totally different from these unsuccessful approaches. Firstly, we rely on top-level academic researchers who identified the real molecular mechanisms that are the direct cause of the diseases: the amyloid protein oligomers which are responsible for an overdose of calcium in brain cells (amyloid pores). Secondly, AmyPore has taken advantages of the recent artificial intelligence revolutions in neurosciences for identifying a new biological code and optimizing the design of AmyPore lead product candidate.

AmyPore solution, called “AmyP53” is the disruptive innovation that has demonstrated to be in the position to overcome these terrible diseases. As a matter of fact, relying upon : - an exclusive license, linked to an international patent owned by the inventors, - recent scientific publications, - and additional recent conclusive tests,

AmyP53 is : - easy to test, - easy to produce worldwide, - easy to administer.

AmyP53 is not only one of the first drug that targets the oligomer cascade, it is the only one that can block the formation neurotoxic oligomers in the membrane of brain cells.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AMINNOVATION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AMINNOVATION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

RoboSynFarm (2019)

Robotic Synthesis Farm

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More